Skip to main content
OpenTrials
Completed

NCT Number: NCT01695018

Early Diagnosis of Oral Cancer by Detecting p16 Methylation

The purpose of this study is to verify the function of p16 methylation diagnostic reagents in early diagnosis of oral cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–78 year

Sex eligibility

All sexes

Study type

Observational

About this study

Background:Oral epithelial dysplasia (OED) is one of the common precancerous lesions among Chinese adults. To investigate the clinical predictive value of p16 methylation diagnostic reagents in the early diagnosis of oral cancer, the investigators carried out the prospective multi-center double-blind cohort study.

Methods:180 patients with histologically confirmed mild or moderate OED were included in the present study. The investigators using p16 methylation diagnostic reagents to analysis of the p16 methylation status in these patients. Building two follow-up queue by p16-methylated and p16-unmethylated. The Statistical analysis used SAS6.12 software. All P-values were two-sided. P<0.05 was considered to test for statistical significance difference.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathological diagnosis of oral lesions meet the epithelial diagnostic criteria for mild to moderate grade OED
  • No local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips
  • Without the OCE treatment history by laser , radiation or chemical
  • Be able to Sign the informed consent

Exclusion criteria

  • Histopathological diagnosis of oral lesions do not meet the epithelium of mild to moderate dysplasia diagnostic criteria; histological diagnosis of severe grade OED or malignant disease
  • Pregnancy or breast-feeding women
  • Serious heart, lung, liver , kidney and other systemic diseases
  • local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips
  • OED treatment history by LASER, radiotherapy, or chemotherapy
  • Tumor and psychiatric patients
  • Patients are unable to cooperate

Treatment and study plan

Primary outcomes

  1. Cancer rate in patients with oral epithelial dysplasia containing or NOT containing p16 methylation

    Time frame: frome 3 months to 63 months

    152 participants were p16 methylated informative. 29 participants were NOT informative because enough DNA was not extracted from their paraffin slides.

    Among these informative cases, oral specimens from 48 patients were p16 methylation positive and 104 patients were p16 methylation negative. The cancer rate in the p16 methylation positive patients during the followup period will be compared with that in the p16 methylation negative patients statistically.

Sponsors and collaborators

Lead sponsor

Peking University

Other

Registry information

Official study title

A Multicentral Prospective Study on Prediction of Malignant Progression of Oral Epithelial Dysplasia With p16 Methylation

Important dates

Study start
2009
Primary completion
2014
First posted
Sep 27, 2012
Registry last updated
Sep 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.